J. Baselga
Oncology · Journal of Clinical Oncology · 2000–2020
A researcher in the Science corpus: 53 papers; trusts 13 researchers and is trusted by 17 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 411 citations into it; #157 of 1,698 by trust here, #22 by citations
- Molecular Biology — 379 citations into it; #7,408 of 17,773 by trust here, #624 by citations
- Pulmonary and Respiratory Medicine — 196 citations into it; #215 of 770 by trust here, #27 by citations
- Radiology, Nuclear Medicine and Imaging — 96 citations into it; #1,423 of 3,265 by trust here, #270 by citations
- Hematology — 41 citations into it
Whom J. Baselga trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- Y. Yarden
- J. Mendelsohn
- N. Hynes
- William Pao
- M. Sliwkowski
- H. Lane
- Lewis C. Cantley
- Fortunato Ciardiello
- Hyun-soo Cho
- Vincent A. Miller
Who trusts J. Baselga overall
- Carlos L. Arteaga
- N. Iqbal
- K. Imai
- Yuichiro Yoshioka
- J. Mendelsohn
- S. Swain
- Y. Yarden
- P. Roberts
- A. Hanker
- Hodgkin Lymphoma
Papers from J. Baselga's perspective
Ordered by how strongly the researchers J. Baselga trusts endorse each paper. Same corpus, a different order for every researcher.
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
- The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. (Molecules and Cells)
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
- Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. (Cell)
- ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors (Nature Reviews. Cancer)
- An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (Molecules and Cells)
- BRAF mutation predicts sensitivity to MEK inhibition (Nature)
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
- The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation (Proceedings of the National Academy of Sciences of the United States of America)
Their papers
- mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. (2006) — 2,588 citations
- Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. (2012) — 1,900 citations
- Systematic identification of genomic markers of drug sensitivity in cancer cells (2012) — 2,417 citations
- Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients (2017) — 2,983 citations
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. (2008) — 815 citations
- PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization (2002) — 842 citations
- Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition (2013) — 2,310 citations
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. (2008) — 1,466 citations
- AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity (2011) — 975 citations
- Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. (2012) — 665 citations
- TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. (2010) — 619 citations
- Sequence analysis of mutations and translocations across breast cancer subtypes (2012) — 1,207 citations
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 (2009) — 1,208 citations
- ESR1 ligand binding domain mutations in hormone-resistant breast cancer (2013) — 1,143 citations
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations (2015) — 1,621 citations
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activity (2008) — 705 citations
- The EGF receptor family as targets for cancer therapy (2000) — 1,389 citations
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2011) — 2,734 citations
- Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. (2009) — 639 citations
- Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. (2007) — 892 citations